Aftab Mahmood, MD
Basic profileCHRISTUS Spohn Hospital Corpus Christi - Memorial
Aftab Mahmood is an Oncology physician affiliated with CHRISTUS Spohn Hospital Corpus Christi - Memorial. OpenAlex indexes 9 publications with 704 citations (h-index 6); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7121 S Padre Island Dr
Suite 102-101,119
Corpus Christi, TX 784124938
Telephone
361-696-6000Provider last certified this registry record 23 Mar 2026.
Clinical trials
- A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Sponsor: Galera Therapeutics, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
107 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202532 payments
- Novartis Pharmaceuticals CorporationProgram year202527 payments
- AstraZeneca Pharmaceuticals LPProgram year202513 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
37.7%RANK Ligand Inhibitor21.5%Denosumab100%Xgeva0%Part D + Part B<11 patientsOther drugs affecting bone structure and mineralization16%Romosozumab-aqqg100%Part B, office-administered≥19 patients+ 3 more classes in this area
Blood & clotting
27.9%Iron, parenteral preparations17%Ferric carboxymaltose80%Ferric derisomaltose20%Part B, office-administered≥31 patientsErythropoiesis-stimulating Agent10.8%Epoetin alfa100%Part B, office-administered≥31 patients+ 5 more classes in this area
Cancer & immunology
20%PD-1 inhibitor18.7%Pembrolizumab100%Part B, office-administered≥19 patientsPlatinum-based Drug0.3%Carboplatin100%Part B, office-administered≥13 patients+ 13 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Case of Rare Subtype of Multiple Myeloma: Secondary Plasma Cell Leukemia
HCA Healthcare Journal of Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Voorhees, MD
CHRISTUS Spohn Hospital Corpus Christi - Memorial
Sridhar Venkatachalam, MD
CHRISTUS Spohn Hospital Corpus Christi - Memorial
Emile Salloum, MD
CHRISTUS Spohn Hospital Corpus Christi - Memorial
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”